We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
6 own
5 watching
Current Price
$25.46
$0.59
(2.37%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
635.54M
52-Week High
30.26900
52-Week Low
6.40000
Average Volume
0.79M
Dividend Yield
--
P/E Ratio
-1.35986159
Market Capitalization635.54M52-Week High30.2690052-Week Low6.40000Average Volume0.79MDividend Yield--P/E Ratio-1.35986159What does the Stockal+Disclaimer.pdf do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
10 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Joshua T. Brumm sold 76,582 shares of Dyne Therapeutics stock in a transaction on Friday, June 9th. The shares were sold at an average price of $13.34, for a total value of $1,021,603.88. Following the completion of the transaction, the insider...
Globe Newswire
1 year ago
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCEPlatform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne...
Globe Newswire
1 year ago
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$25.46
$0.59
(2.37%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.